Long-term treatment with a glucagon-like peptide-1 receptor agonist reduces ethanol intake in male and female rats
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Given the limited efficacy of available pharmacotherapies for treatment of alcohol use disorder (AUD), the need for new medications is substantial. Preclinical studies have shown that acute administration of glucagon-like peptide-1 receptor (GLP-1R) agonists inhibits various ethanol-related behaviours, indicating this system as a potential target for AUD. However, the effects of long-term systemic treatment of GLP-1R agonists on ethanol intake in male and female rodents are to date unknown. Therefore, we investigated the effects of 9 or 5 weeks of once weekly administration of dulaglutide, a long-acting GLP-1R agonist, on ethanol intake in male and female rats. The ethanol intake during treatment discontinuation was also monitored. In an initial attempt to identify preliminary underlying mechanisms, the effects of 9 weeks of once weekly dulaglutide treatment on monoaminergic signalling in reward-related areas were explored in both sexes. We found that 9 or 5 weeks of once weekly dulaglutide treatment reduced ethanol intake and preference in male and female rats. Following discontinuation of dulaglutide treatment, the decrease in ethanol consumption was prolonged in males, but not females. We demonstrated that 9 weeks of dulaglutide treatment differentially influenced monoaminergic signalling in reward-related areas of male and female rats. Collectively, these data imply that the GLP-1R attracts interest as a potential molecular target in the medical treatment of AUD in humans: more specifically, dulaglutide should be evaluated as a potential medication for treatment thereof.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug Addiction, Dysregulation of Reward, and Allostasis
Koob, G. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00195-0 · Cited by 2,953
Grant, B. F., Goldstein, R. B., Saha, T. D., Chou, S. P., Jung, J., Zhang, H., Pickering, R. P., Ruan, W. J., Smith, S. M., Huang, B., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.0584 · Cited by 2,556
Drugs of abuse: anatomy, pharmacology and function of reward pathways
Koob, G. F. (1992) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(92)90060-j · Cited by 2,070
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Bettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12824 · Cited by 374
Kanoski, S. E., Rupprecht, L. E., Fortin, S. M., De Jonghe, B. C., & Hayes, M. R. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.12.022 · Cited by 273
Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon
Srivastava, G., & Apovian, C. (2018) · Current Obesity Reports · doi:10.1007/s13679-018-0300-4 · Cited by 232
Urban, N. B. L., Kegeles, L. S., Slifstein, M., Xu, X., Martinez, D., Sakr, E., Castillo, F., Moadel, T., O'Malley, S. S., Krystal, J. H., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.005 · Cited by 223
The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents
Egecioglu, E., Steensland, P., Fredriksson, I., Feltmann, K., Engel, J. A., & Jerlhag, E. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.11.009 · Cited by 207
Self-citation
Research works printed but not linked: 33
- Naglich, A. C., Lin, A., Wakhlu, S. & Adinoff, B. H. Systematic review of combined pharmacotherapy for the treatment of alcohol use disorder in patients without comorbid conditions. CNS drugs 32, 13–31 (2018). · DOI
- Akbar, M. et al. Medications for alcohol use disorders: an overview. Pharmacol. Therapeutics. 185, 64–85 (2018). · DOI · Paper page
- Jerlhag, E. Gut-brain axis and addictive disorders: a review with focus on alcohol and drugs of abuse. Pharm. Ther. 196, 1–14 (2019). · DOI · Paper page
- Farokhnia, M. et al. Ghrelin: from a gut hormone to a potential therapeutic target for alcohol use disorder. Physiol. Behav. 204, 49–57 (2019). · DOI · Paper page
- Holst, J. J. The physiology of glucagon-like peptide 1. Physiol. Rev. 87, 1409–1439 (2007). · DOI · Paper page
- Glaesner, W. et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab. Res. Rev. 26, 287–296 (2010). · DOI · Paper page
- Shirazi, R. H., Dickson, S. L. & Skibicka, K. P. Gut peptide GLP-1 and its analogue, Exendin-4, decrease alcohol intake and reward. PLoS ONE 8, e61965 (2013). · DOI · Paper page
- Thomsen, M. et al. The glucagon-like peptide 1 receptor agonist exendin-4 decreases relapse-like drinking in socially housed mice. Pharm. Biochem. Behav. 160, 14–20 (2017). · DOI
- Vallof, D. et al. The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents. Addict. Biol. 21, 422–437 (2016). · DOI · Paper page
- Smith, L. L. et al. Dulaglutide (Trulicity): the third once-weekly GLP-1 agonist. P T: Peer-Reviewed J. Formul. Manag. 41, 357–360 (2016).
- Usborne, A. et al. An Investigative study of pancreatic exocrine biomarkers, histology, and histomorphometry in Male Zucker Diabetic Fatty (ZDF) rats given dulaglutide by subcutaneous injection twice weekly for 13 weeks. Toxicol. Pathol. 43, 1093–1102 (2015). · DOI
- Simms, J. A. et al. Intermittent access to 20% ethanol induces high ethanol consumption in Long-Evans and Wistar rats. Alcohol Clin. Exp. Res. 32, 1816–1823 (2008). · DOI · Paper page
- Prieto-Garcia, L. et al. Ghrelin and GHS-R1A signaling within the ventral and laterodorsal tegmental area regulate sexual behavior in sexually naive male mice. Psychoneuroendocrinology 62, 392–402 (2015). · DOI
- Sorensen, G., Caine, S. B. & Thomsen, M. Effects of the GLP-1 agonist exendin-4 on intravenous ethanol self-administration in mice. Alcohol Clin. Exp. Res. 40, 2247–2252 (2016). · DOI
- Thomsen, M. et al. Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys. Psychopharmacology (Berl.) 236, 603–611 (2018). · DOI · Paper page
- Ramchandani, V. A. et al. A genetic determinant of the striatal dopamine response to alcohol in men. Mol. Psychiatry 16, 809–817 (2011). · DOI · Paper page
- Yoder, K. K. et al. Heterogeneous effects of alcohol on dopamine release in the striatum: a PET study. Alcohol Clin. Exp. Res. 31, 965–973 (2007). · DOI · Paper page
- Yoshimoto, K. et al. Alcohol enhances characteristic releases of dopamine and serotonin in the central nucleus of the amygdala. Neurochemistry Int. 37, 369–376 (2000). · DOI
- Engel, J. A. et al. Biochemical and behavioral evidence for an interaction between ethanol and calcium channel antagonists. J. Neural Transm. 74, 181–193 (1988). · DOI
- Weiss, F., Lorang, M. T., Bloom, F. E. & Koob, G. F. Oral alcohol self-administration stimulates dopamine release in the rat nucleus accumbens: genetic and motivational determinants. J. Pharm. Exp. Ther. 267, 250–258 (1993).
- Wise, R. A. & Bozarth, M. A. Brain mechanisms of drug reward and euphoria. Psychiatr. Med. 3, 445–460 (1985).
- Leggio, B. et al. Sardinian alcohol-preferring and non-preferring rats show different reactivity to aversive stimuli and a similar response to a natural reward. Brain Res. 973, 275–284 (2003). · DOI
- Wise, R. A. & McDevitt, R. A. Drive and reinforcement circuitry in the brain: origins, neurotransmitters, and projection fields. Neuropsychopharmacology 43, 680–689 (2018). · DOI
- Umpierrez, G. E. et al. Lack of lipotoxicity effect on {beta}-cell dysfunction in ketosis-prone type 2 diabetes. Diabetes Care. 33, 626–631 (2010). · DOI
- Raun, K. et al. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 56, 8–15 (2007). · DOI · Paper page
- Lopez-Ferreras, L. et al. Lateral hypothalamic GLP-1 receptors are critical for the control of food reinforcement, ingestive behavior and body weight. Mol. Psychiatry 23, 1157–1168 (2018). · DOI · Paper page
- Gu, G. et al. Glucagon-like peptide-1 in the rat brain: distribution of expression and functional implication. J. Comp. Neurol. 521, 2235–2261 (2013). · DOI · Paper page
- Milicevic, Z. et al. Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide. Diabetes Obes. Metab. 18, 533–536 (2016). · DOI · Paper page
- Reiner, D. J. et al. Glucagon-like peptide-1 receptor signaling in the lateral dorsal tegmental nucleus regulates energy balance. Neuropsychopharmacology 43, 627–637 (2018). · DOI
- Hayes, M. R., Skibicka, K. P. & Grill, H. J. Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation. Endocrinology 149, 4059–4068 (2008). · DOI · Paper page
- Suchankova, P. et al. Ghrelin receptor (GHS-R1A) antagonism suppresses both alcohol consumption and the alcohol deprivation effect in rats following long-term voluntary alcohol consumption. PLoS ONE 8, e71284 (2013). · DOI · Paper page
- Egecioglu, E. et al. Ghrelin increases intake of rewarding food in rodents. Addict. Biol. 15, 304–311 (2010). · DOI · Paper page
- Witkiewitz, K., Litten, R. Z. & Leggio, L. Advances in the science and treatment of alcohol use disorder. Sci. Adv. 5, eaax4043 (2019). · DOI · Paper page
Cited by
The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders
Klausen, M. K., Thomsen, M., Wortwein, G., & Fink‐Jensen, A. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15677 · Cited by 259
“Dulaglutide treatment was tested in both male and female rats and was found to reduce alcohol intake more in male rats than in female rats (Vallöf et al., 2020).”
BackgroundSemaglutide reduces alcohol intake and relapse-like drinking in male and female rats
Aranäs, C., Edvardsson, C. E., Shevchouk, O. T., Zhang, Q., Witley, S., Blid Sköldheden, S., Zentveld, L., Vallöf, D., Tufvesson-Alm, M., & Jerlhag, E. (2023) · eBioMedicine · doi:10.1016/j.ebiom.2023.104642 · Cited by 158
Self-citationEffects of dulaglutide on alcohol consumption during smoking cessation
Probst, L., Monnerat, S., Vogt, D. R., Lengsfeld, S., Burkard, T., Meienberg, A., Bathelt, C., Christ-Crain, M., & Winzeler, B. (2023) · JCI Insight · doi:10.1172/jci.insight.170419 · Cited by 94
“These results were largely reproduced using liraglutide (8), dulaglutide (9), and semaglutide (10).”
BackgroundQeadan, F., McCunn, A., & Tingey, B. (2025) · Addiction · doi:10.1111/add.16679 · Cited by 90
Jerlhag, E. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1063033 · Cited by 80
“These dulaglutide-mediated reductions in alcohol drinking and preference for alcohol were also evident in female rats (Vallof et al., 2020), an outcome that was not seen previously.”
BackgroundResultSelf-citation
Metadata
- Authors
- Vallöf, D., Kalafateli, A. L., & Jerlhag, E.
- Venue
- Translational Psychiatry
- Published
- 2020-07-16
- Volume
- 10
- Issue
- 1
- Pages
- 238-238
- ISSN
- 2158-3188 (ISSN-L)
- OpenAlex
- W3042895144
- Cited by
- 72
- References
- 17
- FWCI
- 2.29
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Funders
- Arvid Carlsson Fonden (n/a)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term treatment with a glucagon-like peptide-1 receptor agonist reduces ethanol intake in male and female rats. https://app.cochat.ai/papers/10.1038/s41398-020-00923-1
- The paper
- Vallöf, D., Kalafateli, A. L., & Jerlhag, E. (2020). Long-term treatment with a glucagon-like peptide-1 receptor agonist reduces ethanol intake in male and female rats. Translational Psychiatry. https://doi.org/10.1038/s41398-020-00923-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.